Material below summarizes the article Limited Efficacy of α-Conopeptides, Vc1.1 and RgIA, to Inhibit Sensory Neuron Cav Current, published on January 16, 2015, in eNeuro and authored by Andrew B. Wright, Yohei Norimatsu, J. Michael McIntosh, and Keith S. Elmslie.
Chronic pain reduces the quality of life for millions of people, and the available treatments are limited and ineffective for many patients. Thus, novel analgesics are a critical area of research.
Strong preclinical evidence supports the analgesic effects of the α-conopeptides, Vc1.1 and RgIA, which block α9α10 nicotinic acetylcholine receptors (nAChRs). However, the analgesic mechanism is controversial. Some evidence supports the block of α9α10 nAChRs as an analgesic mechanism, while other evidence supports the inhibition of N-type CaV (CaV2.2) channels via activation of GABAB receptors.
Access to the full article is available to SfN members.
Neuronline is a benefit of SfN membership. Renew your membership now to make sure you don’t lose access.
.png?h=423&w=750&la=en&hash=0183EBA50F51DFCC36ADEB5E7AEB5E0D87F8A7EA)
.png?h=423&w=750&la=en&hash=4890EC561E6BC83F646E0AD45CC1E31D666B7BEB)
.png?h=423&w=750&la=en&hash=F1FD544DD9CF144A59ACE1AEC3F87F3558711B1B)
